MINNEAPOLIS, Oct. 20, 2015 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc., (OTCPink:SNBP), a biopharmaceutical company developing therapies for the treatment of pancreatic diseases, announced today that the Company will present pre-clinical data in three abstracts on its lead development candidate, SBP-101, at the 2015 American Pancreatic Association (APA) annual meeting being held November 4-7, 2015 in San Diego, CA.
"We are excited to present three abstracts featuring pre-clinical data from our lead drug candidate SBP-101, a first-in-class proprietary polyamine compound designed to exert a therapeutic effect in a mechanism specific to the pancreas," stated David Kaysen, President and CEO of Sun BioPharma. "This data formed the basis for the Investigational New Drug (IND) approval that was recently granted by the United States Food & Drug Administration (FDA) and drove the development of the Phase I clinical study expected to initiate in Australia by the end of the year, and in the U.S. in the first half of 2016."
Thursday, November 5: Poster Session I
7:00 am – 6:00 pm (Main Poster session with authors present from 12:00 – 2:00 pm)
Evaluation of Human Pancreatic Cancer Cell Viability Following Administration of SBP-101 in the Presence and Absence of Gemcitabine and Nab-Paclitaxel (Abstract #15035)
C. Baker1, S. Arora2, S. Gagnon2, M. Cullen2 and A. Shah2
1 Biocurity, Inc., New Smyrna Beach, FL; 2Sun BioPharma, Inc., Gainesville, FL
SBP-101 Induces Apoptosis in Mouse Pancreatic Acinar Cells and Inhibits Polyamine Induced Proliferation (Abstract #15275)
A. Sareen1, A.Saluja1, A. Shah2, R. Dawra1
1Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis MN; 2Sun BioPharma, Inc., Gainesville, FL
Friday, November 6: Poster Session II
7:00 am – 6:30 pm (Main Poster session with authors present from 12:00 – 2:00 pm)
Efficacy of SBP-101 with or without Gemcitabine and/or Nab-paclitaxel in a Murine Xenograft Model of Human Pancreatic Ductal Adenocarcinoma (Abstract #15034)
A. Shah1, S. Gagnon1, P. Milani de Marval2, A. Kiorpes1, and M. Cullen1
1Sun BioPharma, Inc., Gainesville, FL; 2Charles River Discovery Services, Morrisville, NC
"Our team at the University of Minnesota is excited about the opportunity to work with the compound SBP-101," said Dr. Ashok Saluja, current secretary-treasurer and past–president of the APA, and lead author on one of Sun BioPharma's presentations. "The compound's novel mechanism of action is showing promise as a candidate for the largely unmet medical needs pertaining to the treatment of pancreatic cancer and pancreatitis."
SBP-101 is a first-in-class proprietary polyamine compound designed to exert therapeutic effects in a mechanism specific to the pancreas. Sun BioPharma originally licensed SBP-101 from the University of Florida in 2011. The molecule has been shown to be highly effective in human pancreatic cancer models, demonstrating superior activity to existing chemotherapy agents. Combination potential has also been shown for pancreatic cancer. SBP-101 is expected to hold an edge over current pancreatic cancer therapies, since it specifically targets the exocrine pancreas and has shown efficacy against primary and metastatic disease in animal models of human pancreatic cancer.
About Sun BioPharma
Sun BioPharma Inc. is a next-generation biopharmaceutical company developing disruptive therapeutics for serious unmet medical needs. The company's initial programs are aimed at diseases of the pancreas, including pancreatitis and pancreatic cancer. Sun BioPharma has scientific collaborations with pancreatic disease experts at The Ohio State University, the Fred Hutchinson Cancer Center in Seattle, Translational Genomics (TGen) in Scottsdale, AZ, Cedars Sinai Medical Center in Los Angeles, the University of Minnesota, the Austin Health Cancer Trials Centre and the Box Hill Hospital in Melbourne, Australia and the Ashford Cancer Centre in Adelaide, Australia. Further information can be found at: www.sunbiopharma.com. Sun BioPharma's common stock currently trades on the OTCPink Exchange under the symbol: SNBP.
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Sun BioPharma, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Sun BioPharma particularly those mentioned in the cautionary statements found in Sun BioPharma's filings with the Securities and Exchange Commission. Sun BioPharma disclaims any intent or obligation to update these forward-looking statements.
CONTACT: EVC Group Investor Contact: Doug Sherk 415-652-9100 Michael Polyviou 212-850-6020 Media Contact: Dave Schemelia 646-201-5431
Source:Sun BioPharma, Inc.